Paul Stoffels, company group chairman for Global R&D Pharmaceuticals at Johnson & Johnson, has a guest blog at CNBC about how "recent advances in science, genomics technologies, biomarkers, and drug development" have coalesced to offer the potential for personalized medicine. Using HIV drug development as an example, Stoffels makes the case that relying on diagnostic expertise throughout the process led not only to more targeted treatment, but also helped the pharma make better drugs.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

In a statement, National Institutes of Health Director Francis Collins says sexual harassment is "morally indefensible" and "unacceptable."

Octopuses might owe their intelligence to their liberal alterations to their genes, Cosmos reports.

Stat News and ProPublica report that African Americans are underrepresented in cancer clinical trials.

In Cell this week: genomic analysis of abdominal aortic aneurysm, effect of probiotics on the microbiome, and more.